Core Insights - Outlook Therapeutics, Inc. is focused on optimizing the standard of care for bevacizumab in treating retinal diseases [1][2] - The company will present at the EURETINA Congress on September 3, 2025, discussing advancements in retinal disease treatment [1] - ONS-5010/LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive marketing authorization in Europe for wet AMD [2] Company Overview - Outlook Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg) [2] - The commercial launch of LYTENAVA™ has commenced in Germany and the UK for the treatment of wet AMD [2] - In the United States, ONS-5010/LYTENAVA™ is currently investigational and would be the first approved ophthalmic formulation of bevacizumab for retinal indications if approved [3]